PI3K/AKT/mTOR Signaling Pathway in Neurodegeneration

PI3K/AKT/mTOR Signaling Pathway in Neurodegeneration

Introduction

The PI3K/AKT/mTOR Signaling Pathway in Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

The PI3K/AKT/mTOR pathway is a central signaling cascade that regulates cell survival, growth, metabolism, protein synthesis, and [autophagy](/entities/autophagy). This pathway is one of the most frequently dysregulated pathways in cancer, but it also plays critical roles in neuronal survival, synaptic plasticity, and proteostasis. In neurodegenerative diseases, PI3K/AKT/mTOR signaling is generally suppressed, contributing to impaired autophagy, synaptic dysfunction, and neuronal death. Understanding this pathway provides insights into therapeutic targeting for Alzheimer's disease (AD), Parkinson's disease (PD), and other disorders. [@brunet2001]

Pathway Components

Upstream Activation

The pathway is activated by various growth factors, neurotrophins, and insulin. Key activators include: [@cantley2002]

| Activator | Receptor | Primary Effect | [@ma2010]
|-----------|----------|---------------| [@rai2022]
| BDNF | TrkB | Neuronal survival, synaptic plasticity | [@hoeffer2010]
| IGF-1 | IGF-1R | Metabolic regulation, neuroprotection | [@swiech2008]
| EGF | EGFR | Proliferation, growth | [@boland2008]
| Insulin | InsulinR | Metabolic homeostasis | [@caccamo2010]
| Neuregulin | ErbB | Myelination, synaptic function | [@oddo2012]

Core Pathway

PI3K/AKT/mTOR Signaling Pathway in Neurodegeneration

Introduction

The PI3K/AKT/mTOR Signaling Pathway in Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

The PI3K/AKT/mTOR pathway is a central signaling cascade that regulates cell survival, growth, metabolism, protein synthesis, and [autophagy](/entities/autophagy). This pathway is one of the most frequently dysregulated pathways in cancer, but it also plays critical roles in neuronal survival, synaptic plasticity, and proteostasis. In neurodegenerative diseases, PI3K/AKT/mTOR signaling is generally suppressed, contributing to impaired autophagy, synaptic dysfunction, and neuronal death. Understanding this pathway provides insights into therapeutic targeting for Alzheimer's disease (AD), Parkinson's disease (PD), and other disorders. [@brunet2001]

Pathway Components

Upstream Activation

The pathway is activated by various growth factors, neurotrophins, and insulin. Key activators include: [@cantley2002]

| Activator | Receptor | Primary Effect | [@ma2010]
|-----------|----------|---------------| [@rai2022]
| BDNF | TrkB | Neuronal survival, synaptic plasticity | [@hoeffer2010]
| IGF-1 | IGF-1R | Metabolic regulation, neuroprotection | [@swiech2008]
| EGF | EGFR | Proliferation, growth | [@boland2008]
| Insulin | InsulinR | Metabolic homeostasis | [@caccamo2010]
| Neuregulin | ErbB | Myelination, synaptic function | [@oddo2012]

Core Pathway

Growth Factor → RTK → PI3K → PIP3 → AKT → mTORC1 → Protein Synthesis
↓
Autophagy Regulation
↓
4E-BP1, S6K → Translation

PI3K (Phosphoinositide 3-kinase): Class I PI3Ks convert PIP2 to PIP3, a lipid second messenger that recruits AKT to the plasma membrane. [@diazruiz2009]

AKT (PKB): AKT is activated by phosphorylation at Thr308 (by PDK1) and Ser473 (by mTORC2). Active AKT phosphorylates numerous substrates regulating survival, metabolism, and protein synthesis. [@liu2013]

mTOR (Mechanistic Target of Rapamycin): mTOR exists in two complexes: [@kim2011]

• mTORC1: mTOR + Raptor + mLST8 - sensitive to rapamycin, regulates translation and autophagy
• mTORC2: mTOR + Rictor + mLST8 - regulates AKT, cytoskeleton, cell survival

PI3K/AKT/mTOR in Alzheimer's Disease

Synaptic Dysfunction

Synaptic loss is the strongest correlate of cognitive decline in AD. BDNF-TrkB-PI3K-AKT signaling is essential for synaptic plasticity and memory. In AD, Aβ oligomers interfere with BDNF signaling, reducing PI3K/AKT activation and contributing to synaptic failure. [@wang2017]

Tau Pathology

AKT directly phosphorylates GSK3β at Ser9, inhibiting its activity and reducing tau phosphorylation. In AD, reduced AKT activity leads to GSK3β hyperactivity and increased tau pathology.

Autophagy Impairment

mTORC1 is a master regulator of autophagy. Hyperactive mTORC1 inhibits autophagy, leading to accumulation of damaged proteins and organelles. However, in AD, the relationship is complex - some studies show elevated mTOR signaling contributing to autophagy inhibition.

Metabolic Dysfunction

Brain insulin resistance is a feature of AD (type 3 diabetes). Impaired insulin-PI3K-AKT signaling contributes to cerebral hypometabolism and cognitive decline.

PI3K/AKT/mTOR in Parkinson's Disease

Neuronal Survival

AKT promotes dopaminergic neuron survival through phosphorylation of BAD (inactivating it), activation of CREB (promoting survival gene expression), and inhibition of GSK3β.

Alpha-Synuclein Toxicity

α-Synuclein aggregation interferes with PI3K/AKT signaling. Phosphorylated AKT levels are reduced in PD brains. Restoring AKT signaling protects against α-synuclein toxicity in cellular and animal models.

Mitochondrial Dysfunction

PI3K/AKT signaling regulates mitochondrial biogenesis through PGC-1α. Impaired AKT signaling contributes to mitochondrial dysfunction in PD.

Autophagy-Lysosomal Pathway

mTORC1 inhibition promotes autophagy, which is protective in PD by clearing α-synuclein aggregates. Rapamycin (mTOR inhibitor) protects against dopaminergic neuron loss in models.

Therapeutic Implications

mTOR Inhibitors

| Drug | Mechanism | Clinical Status | Neurodegeneration |
|------|-----------|----------------|-------------------|
| Rapamycin | mTORC1 inhibitor | Approved (transplant) | Preclinical AD/PD |
| Everolimus | mTORC1 inhibitor | Approved (oncology) | Preclinical |
| AZD8055 | mTORC1/2 inhibitor | Phase I/II | Preclinical |
| Torin 1 | mTORC1/2 inhibitor | Preclinical | Preclinical |

AKT Activators

| Agent | Target | Development |
|-------|--------|-------------|
| BDNF | TrkB agonist | Preclinical |
| IGF-1 | IGF-1R | Clinical trial (AD) |
| AKT activator SC79 | AKT | Preclinical |

Challenges

• Complex, context-dependent pathway effects
• Autophagy induction vs. protein synthesis inhibition
• Timing of intervention
• Off-target effects

Cross-Links

• See also: [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway) - mTOR's role in autophagy
• See also: [BDNF Signaling](/mechanisms/bdnf-neurotrophin-signaling-pathway) - Upstream activation
• See also: [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway) - PI3K/AKT in synapses
• See also: [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway) - Cross-talk
• See also: [Insulin Signaling](/mechanisms/insulin-signaling-neurodegeneration) - Brain insulin resistance
• [See also: [Tau Pathology](/mechanisms/tau-pathology)](/proteins/tau)

Mermaid Diagram: PI3K/AKT/mTOR in Neurodegeneration

External Links

• [PubMed - Research Papers](https://pubmed.ncbi.nlm.nih.gov/)
• [Allen Brain Atlas](https://brain-map.org/)
• [BrainSpan Atlas](https://brainspan.org/)

See Also

• [Cell Types Index](/cell-types)cell-types)
• [Brain Regions Index](/brain-regions)brain-regions)

Background

The study of the PI3K/AKT/mTOR Signaling Pathway in Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

• Research progress on the role of acupuncture in Alzheimer's disease based on the PI3K/AKT/mTOR signaling pathway. (J Alzheimers Dis, 2026). https://pubmed.ncbi.nlm.nih.gov/41724495/
• BTK inhibition suppresses neuroinflammation and neurodegeneration in amyotrophic lateral sclerosis. (Brain, 2026). https://pubmed.ncbi.nlm.nih.gov/41710977/
• The protective effect of febuxostat in a rotenone mouse model of Parkinson's disease: the interplay between PI3K/Akt/mTOR, [GSK-3β](/entities/gsk3-beta), and Nrf2/HO-1 signaling pathways. (J Pharm Pharmacol, 2026). https://pubmed.ncbi.nlm.nih.gov/41689820/
• Beyond Neurotrophins: A Proposed Neurotrophic-Epigenetic Axis Mediated by Non-Coding RNA Networks for Hericium erinaceus Bioactives-A Hypothesis-Driven Review. (Int J Mol Sci, 2026). https://pubmed.ncbi.nlm.nih.gov/41683696/
• Xanthohumol: Mechanistic Actions and Emerging Evidence as a Multi-Target Natural Nutraceutical. (Nutrients, 2026). https://pubmed.ncbi.nlm.nih.gov/41683342/

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 14 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |

Overall Confidence: 41%

References